USRM Financial Statements From 2010 to 2026
| USRM Stock | USD 0.0001 0.00 0.00% |
Check US Stem financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among US Stem's main balance sheet or income statement drivers, such as , as well as many indicators such as . USRM financial statements analysis is a perfect complement when working with US Stem Valuation or Volatility modules.
USRM |
US Stem Cell Company Return On Asset Analysis
US Stem's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current US Stem Return On Asset | -8.45 |
Most of US Stem's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, US Stem Cell is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, US Stem Cell has a Return On Asset of -8.4476. This is 3.46% lower than that of the Biotechnology sector and 64.21% lower than that of the Health Care industry. The return on asset for all United States stocks is notably higher than that of the company.
US Stem Cell Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining US Stem's current stock value. Our valuation model uses many indicators to compare US Stem value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across US Stem competition to find correlations between indicators driving US Stem's intrinsic value. More Info.US Stem Cell is rated third in return on asset category among its peers. It is rated below average in operating margin category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the US Stem's earnings, one of the primary drivers of an investment's value.About US Stem Financial Statements
US Stem investors utilize fundamental indicators, such as revenue or net income, to predict how USRM Pink Sheet might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. Stem Cell, Inc. was incorporated in 1999 and is headquartered in Sunrise, Florida. US Stem operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetOther Information on Investing in USRM Pink Sheet
US Stem financial ratios help investors to determine whether USRM Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in USRM with respect to the benefits of owning US Stem security.